Bladder cancer is one of the most common cancers in the world and ranks 9th. In the urogenital system, it is the most common malignancy after prostate [1]. With its increasing incidence, it has become the fourth most common malignancy in the male patient group, after lung, prostate and colorectal cancer. For this reason, in addition to its case-based importance, it is also considered as a public health problem.